Prescient Pharma is an innovative drug development and pharmaceutical company based in Canton, MA. We perform research to develop drugs for anti-aging, pulmonary diseases and cancers. Our goal is to produce effective drug products to improve patients lives. We focus on bringing life-improving drugs to patients in an accelerated manner. We also offer a broad range of contract Investigative Pathology and Cytopathology services. We have a team of experienced investigative pathologists and network of Board certified pathologists and cytopathologists. Our research facility is led by drug development experts, who are dedicated to the discovery of better drugs. We strive to accelerate the drug development process, from discovery and clinical trials to commercialization. Our priority is to develop effective medications faster and at lower cost. Prescient Pharma is developing small molecules to target proliferative disease states (malignant tumors), pulmonary diseases, myocardial infarction and stroke. Prescient Pharma is also the parent company of Prescient Pharma X, a subsidiary focusing on improving cellular health and longevity through medicinals and nutraceuticals. Our mission: To improve the duration and quality of life with unique approaches supported by thorough scientific methodology. Aging is a leading risk factor for cancer development and neurodegenerative diseases. It is our belief that Cellular Rejuvenation will result in either delayed onset or actual reduction in the incidence of proliferative and neurodegenerative disease states. The Team: • Paul Idelevich, M.D., CEO • Kenneth Reed, M.D., Vice President • Anna Idelevich, Ph.D., MBA, Chief Scientist • Ed Khalili, J.D., Pharm.D., COO • Domenico Lazzaro, MD Scientist Prescient Pharma was co-founded by Paul Idelevich MD and Kenneth Reed MD, both physicians with a passion for biotechnology and drug development.